Antev Ltd. Secures Reduced Royalty Deal to Boost Teverelix Economic Profile
I'm PortAI, I can summarize articles.
Antev Ltd., a subsidiary of Medicus Pharma, has amended its license with LifeArc, resulting in a reduced royalty rate for Teverelix to 2%. This strategic move aims to enhance the economic profile of Teverelix.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments